These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 12360407

  • 21. Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis.
    Kontny HU, Hämmerle K, Klein R, Shayan P, Mackall CL, Niemeyer CM.
    Cell Death Differ; 2001 May; 8(5):506-14. PubMed ID: 11423911
    [Abstract] [Full Text] [Related]

  • 22. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.
    MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM.
    Cancer Res; 2005 Dec 15; 65(24):11265-70. PubMed ID: 16357130
    [Abstract] [Full Text] [Related]

  • 23. Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells.
    Lacour S, Micheau O, Hammann A, Drouineaud V, Tschopp J, Solary E, Dimanche-Boitrel MT.
    Oncogene; 2003 Mar 27; 22(12):1807-16. PubMed ID: 12660816
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells.
    Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ.
    J Immunol; 1998 Sep 15; 161(6):2833-40. PubMed ID: 9743343
    [Abstract] [Full Text] [Related]

  • 27. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP, Zisman A, Bonavida B.
    Prostate; 2002 Dec 01; 53(4):286-99. PubMed ID: 12430140
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
    Tomek S, Horak P, Pribill I, Haller G, Rössler M, Zielinski CC, Pils D, Krainer M.
    Gynecol Oncol; 2004 Jul 01; 94(1):107-14. PubMed ID: 15262127
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Defining characteristics of Types I and II apoptotic cells in response to TRAIL.
    Ozören N, El-Deiry WS.
    Neoplasia; 2002 Jul 01; 4(6):551-7. PubMed ID: 12407450
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells.
    Knight MJ, Riffkin CD, Muscat AM, Ashley DM, Hawkins CJ.
    Oncogene; 2001 Sep 13; 20(41):5789-98. PubMed ID: 11593384
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1.
    MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB, Dyer MJ, Cohen GM.
    Cell Death Differ; 2005 Jul 13; 12(7):773-82. PubMed ID: 15861184
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.